Bioasis Technologies Inc. Announces Warrant Extension

GUILFORD, Conn. — () — BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017. Bioasis intends to extend the expiry date of the warrants from April 11, 2019 until April 11, 2021.

The exercise price of $1.00 per share and all other terms of the warrants will remain unchanged for the extended exercise period. The extension is subject to approval from the TSX Venture Exchange.

About Bioasis

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’ internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gaucher’s Disease Type II. The Company maintains headquarters in Guilford, Connecticut. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the Company, please visit www.bioasis.us.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:

Deborah Rathjen
deborah@bioasis.us
+1 203 533 7082

Christina Tartaglia
Stern Investor Relations
christina@sternir.com
+1 212 362 1200